Score Pharma is a pre-clinical stage biotech pioneering the development of more effective second-generation antibody therapeutics (AbThx) from existing products. Our patent-pending CoreX™ platform is a discovery engine that accelerates the development of best-in-class biobetter antibody therapeutics. We transform existing clinically validated products into second-generation, more potent therapeutics while retaining all the quality attributes of the original product. The CoreX™ platform produces a specific alteration in the drug structure known to dramatically improve the efficacy, qualifying it as a new biological entity (NBE). Although our initial focus is oncology, our CoreX™ platform is disease-agnostic and can be applied to multiple indications. www.scorepharma.com

Nova Mentis Pharma is a company dedicated to the search for “New Beginnings” and providing high quality solutions towards unmet medical needs. Our focused strategy is to develop medicines that limit toxicities, off target side effects and improve our patients’ quality of life. Nova Mentis is pursuing these goals in a manner that is driven exclusively by needs of our patients and not high profits.Our current pipeline includes medicine for the acute rescue of obstructive hypertrophic cardiomyopathy (HOCM) and atrial fibrillations (AF), pulmonary hypertension (PHT) and infectious diseases including Covid-19. We are currently generating data that not only provide proof of concept but also significantly reduced off target effects while minimizing other general toxicities. True to our mission, we have a rigorous selection process for both medicines and disease indications enabling us to provide the best value for our patients.We are presently examining partnerships as well as non-diluting collaborations with forward-looking biotechnology and pharmaceutical companies in the areas of Drug Development, Novel Device Engineering, and Product Advancement. Our partners are expected to hold the same high standards regarding our patients and our mission towards the treatment of current unmet medical needs.We are also currently seeking support from visionary scientific foundations and private individuals as well as exploring the engagement of Venture Capital Firms.www.novamentispharma.com

Heart Failure has been recognized to be an inflammatory disease for over 20 years. However, several attempts to use immunomodulation to prevent and treat heart failure have failed, due to toxicity or lack of efficacy. i-Cordis brings together a world class team of cardiac immunologists and drug development experts to harvest the power of immunomodulation and address what is arguably the current greatest unmet need in cardiology: Heart Failure with Preserved Ejection Fraction. In order to overcome the issues faced by prior teams, i-Cordis is deliberately using recent insights in cardiac immunology to optimize a marketed drug, pirfenidone. Pirfenidone is arguably the most extensively studied immunomodulatory drug with cardioprotective effects. Its cardioprotective effects have been documented in 3 different preclinical species across multiple models of cardiac dysfunction in works reported in > 30 peer reviewed publications. Recently it has also been studied in humans in phase II clinical trials. i-Cordis is leveraging the knowhow of its team to eliminate pirfenidone's drawbacks and develop a new molecular entity that is well poised to revolutionize the treatment of HFpEF.www.i-cordis.com/home

Quench Life Sciences is a Chemical Development Company based in Hyderabad, India. Quench provides range of services – Early & Late Stage Development using QbD principles, Custom Synthesis & Multi-FTE’s. Quench has designed its service model with speed & real time communication at its core.1) Early & Late-Stage Development using QbD Principles Synthetic Chemistry2) Fate & Purge Studies of Impurities3) Custom Chemical Synthesis4) Discovery Synthesishttps://quenchlifesciences.com

Take a walk on the fiery to mild side with us! We invented recipes that matched the spiciness of the pepper with the sweet of confections. While most people attempt to create potions that will light you on fire and give you bragging rights to your friends, we choose to focus on the flavor of the peppers and marrying those unique tastes with other ingredients to give you, the customer, an enjoyable epicurean experience.We use only fresh, organic, home or locally grown produce and hand make all our products. We hope you enjoy savoring our goodies as much as we enjoy making them. We are always exploring and conceiving of new recipes so stay tuned for our latest creations.www.untamedspice.comhttps://m.facebook.com/UntamedSpiceshttps://www.instagram.com/untamed_spice

BIO Alabama is the leading advocate for the state’s bioscience and healthcare industries, such as pharmaceuticals, medical devices, hospitals, research testing, and medical labs.Alabama’s biosciences industry currently generates $7.3 billion in annual economic activity, and supports nearly 48,000 direct and indirect jobs statewide.www.bioalabama.com

Foresight Biosciences, Inc. is an Associate Company of the HudsonAlpha Institute for Biotechnology, which is a leading center for genome research located in Huntsville, Alabama. Our goal is to innovate the advancement of glycobiology research and protein therapeutics. Our specific aim is to develop solutions in protein-based drug development that address issues associated with the production of therapeutic proteins derived from non-human cells. With these goals in mind, Foresight is developing technologies to facilitate protein posttranslational modification, glycoconjugation and glycan analysis. These approaches currently include the development of enzymes and assay for glycoprotein terminal fingerprint analysis and kits for repairing and modifying protein glycosylation. Our aspiration is the utilization of this technology to advance our own in-house research efforts and our own therapeutic development.We also recognize our technology is not strictly limited to the field of biotechnology; therefore, we are continually engaged on bridging the gap between research and commercialization across the expanse of all industries in which a strong component of glycoengineering exists. Foresight’s vision is to become the premier technology provider of glycobiology-related products for research and development for companies.www.foresight-bio.com@foresightbio (Twitter)

External Advisory Committee (EAC) members are experienced industry drug hunters with career focus in assay development/screening, medicinal chemistry, computational chemistry, drug metabolism/pharmacokinetics (DMPK), in vitro pharmacology, and in vivo pharmacology. EAC will evaluate and select projects for matching Micro Grant funding based on (1) scientific merit, (2) how completing the proposed project will facilitate project advancement, and (3) probability of success.Website: https://cdd.wustl.edu

Providing scientific and business expertise / guidance towards product development enabling profit generation.Key Strengths & Expertise:• Drug Discovery & Preclinical Development through IND-enabling studies• Medicinal Chemistry: Small Molecule, Biologics, & Polymer Conjugate Drug Design, Synthesis, Characterization•Therapeutic Areas: Oncology, Pain, Metabolic Diseases, Inflammation, Antiviral, Rare Diseases• Critical evaluation of new concepts / Competitive Assessment / Therapeutic Area Analysis• Strong leadership and staff development building high functioning global cross-functional teams• Project leadership experience in multiple therapeutic areas from drug discovery through IND-enabling• Management of research collaborations and external resources, i.e. CROs• Excellent verbal and written communication• Intellectual property strategy, generation• Due diligence support for investors, potential partners, or M&A• Organization & moderating of therapeutic area / technology focused Advisory Boards• Design and execution of controlled substance program and license to include Schedules II-V• Implementation of global E-Notebook and Cheminformatics system• Additional expertise in leadership development including Lominger leadership competencies, emotional intelligence, conflict resolution, and organizational savvy• Software

Roles:- Member of the Senior Leadership Team, Research Executive Team and Head of Chemistry- Routinely communicate to Executive Management the status of highly visible research programs- Develop Nektar platform and pipeline with novel drug development candidates- Support discovery, pre-clinical, and IND-enabling activities leading to 1-2 development candidates/yr- Reviewer of non-clinical sections for both IND and NDA submissions- Member of the Nektar / Astra Zeneca Movantik™ (Naloxegol) team from Discovery to Launch- Co-Inventor of NKTR-181 (non-addicting opioid)- Maintain and develop Nektar’s research patent portfolio with legal department- Thoughtful selection of targets, diseases, define target product profiles- Identify, support, and evaluate external business collaboration opportunities - Deliver key scientific presentations to potential investors and business partners. - Responsible for execution of annual Research Symposium & Advisory Boards- Efficient management of research budget with corporate finance: ~$50 millionLeadership Training:- Leading for Organizational Impact, CCL- Becoming a Conflict Competent Leader - Developing Emotional Intelligence, Talent SmartAchievements:- Skillful & accomplished in building a lean, highly motivated & productive, efficient,creative, unified and successful chemistry team. - Dynamic leadership that focuses on a sense of urgency, accountability, project cycle times, employee buy-in, and scientific excellence. Experience complementing internal research infrastructure with outsourcing to CROs.- Built a robust pipeline of novel drug candidates across a number of therapeutic areas (Immunotherapy, Rare Diseases, Oncology, Pain)- Successfully lead global project teams ~ 20 scientists to rapidly deliver critical results - Global implementation of a E-Notebook & Chemical Informatics system to increase efficiency & transparency.- Presentations (30+); peer reviewed publications (30); co-inventor 40+ patents

• Successful leadership of the small molecule medicinal chemistry group resulting in a highly productive and efficient team of 10 scientists with $5.0 million budget. • Build and maintain a pipeline of novel small molecule candidates across a number of therapeutic areas (Oncology, Pain, Antiviral, Antihistamine, and Infectious Disease). • Actively contribute and encourage inter-disciplinary communication as a core team member on 9 small molecule pre-clinical and development programs.• Successfully lead project teams of up to 12 scientists through matrix management across 3 sites to rapidly deliver critical results. • Liase with stakeholders in other discovery departments to evaluate biological rationale / available assets regarding new targets. • Design and construct in collaboration with IT a global SharePoint site for all of Research to enhance inter- and intra-departmental communication and promote transparency. • Initiate the employment of in silico modeling to support structure-guided drug design and successfully collaborated / managed a computational / molecular modeling consultant for results. • Manage with high productivity several Contract Research Organizations (CROs) both foreign and domestic to support and supplement internal resources. • Implementation in collaboration with EH&S a controlled substance program and license for research at Huntsville, AL site to include Schedules II-V.• Represent Nektar’s science to partners, investors, Advisory and KOL boards, consultants, and the scientific community.

Directed activity of 10 scientists in the small molecule group which is responsible not only for all medicinal chemistry aspects of applying the Nektar PEGylation technology to drug molecules from rational design through screening but also is a major source of ideas, concepts, and new IP generation for the Company’s pharmaceutical development. Successfully managed a number of CROs to support medicinal chemistry efforts. Additional responsibilities included leading and participating on teams at three sites including Hyderabad, India; San Carlos, CA and Huntsville, AL. Integral in the transferring of programs from Discovery/Research Phase to Development. Managed up to $2.0 million budget.

Directed activity of 10 scientists in the small molecule group which is responsible not only for all medicinal chemistry aspects of applying the Nektar PEGylation technology to drug molecules from rational design through screening but also is a major source of ideas, concepts, and new IP generation for the Company’s pharmaceutical development. Successfully managed a number of CROs to support medicinal chemistry efforts. Additional responsibilities included leading and participating on teams at three sites including Hyderabad, India; San Carlos, CA and Huntsville, AL. Integral in the transferring of programs from Discovery/Research Phase to Development. Managed up to $2.0 million budget.

• Successful leadership of the Drug Discovery & Chemical Innovation Group: Synthetic Organic Research Scientists – 3 Ph.D., 3 M.S./B.S. level synthetic chemists; Analytical Research Scientists – 1 Ph.D, 2 M.S./B.S. level analytical chemists. • Directed and managed medicinal / synthetic chemistry activities (derivatization of proteins, peptides, and small molecules with assessment of bioactivity through in vitro, in vivo, and oral bioavailabilty screening) on up to 10 projects according to company project priorities• Interacted and promoted scientific discussions with cell pharmacology, animal pharmacology, analytical chemistry, clinical & regulatory, chemical development & manufacturing, formulation, and computational chemistry• Project team lead on 5 different successful cross-functional project teams; 3 of which were partnered with Top 5 Pharmaceutical Companies (GSK, Pfizer, and BMS) in the areas of diabetes, metabolic disease, and obesity.• Facilitated team meetings, mediated issue resolution, assigned action items, drove projects to completion over aggressive timelines• Reviewer, primary synthetic chemist and member of IND filing team for APAZATM (small molecule for IBD)• Participated in due diligence sessions with outside companies for product out-licensing• Created and worked with CRO to generate Nobex Oligomer Library – 500 compounds that were prepared by automated & parallel syntheses techniques• Scientific liaison and consultant with Business Development for Technology Application Deals• Identification and evaluation of New Technologies or Drug Discovery Opportunities for in-licensing or creative partnerships • Participated in intellectual property brainstorming sessions • Prepared and reviewed patent applications in collaboration with in-house counsel• Represented Nobex’s science to partners, investors, consultants, and the scientific community• Served as Chemical Hygiene Officer on safety team

Research under the direction of Dr. Jonathan S. Lindsey (Glaxo Distinguished University Professor of Chemistry) included: 1) Investigation of conditions in porphyrin-forming reactions using an automated chemistry workstation and 2) Synthesis and development of novel porphyrin systems vital to the understanding of electronic communication in the design of efficient molecular photonic devices.

A chemical company involved with the development and manufacture of functionalized biocompatible poly(ethylene glycol) for academic, pharmaceutical, and biotechnical applications. Responsibilities included: Syntheses and development of poly(ethylene glycol) derivatives, execution of GMP procedures for large scale polymer production, and organization of chemical laboratory at company's inception.